Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Kidney cancer, computer illustration. Toripalimab plus axitinib can improve progression-free survival, when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell ...

Please provide your email address to receive an email when new articles are posted on . Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS ...

Please provide your email address to receive an email when new articles are posted on . Patients who received torpialimab in addition to nab-paclitaxel had longer median PFS (8.4 months vs. 5.6 months ...

The median overall survival was 31.5 months in the disitamab vedotin-toripalimab arm and 16.9 months in the chemotherapy arm. First-line treatment with disitamab vedotin and toripalimab can improve ...

Notching another deal in its efforts to extend the global reach of toripalimab, Junshi Biosciences Co. Ltd. granted Dr. Reddy’s Laboratories Ltd. rights to develop and commercialize the PD-1 inhibitor ...

The application is supported by data from the phase 2 POLARIS-02 and phase 3 JUPITER-02 studies. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...

Shanghai Junshi Biosciences (OTCPK:SHJBF) said China's National Medical Products Administration (NMPA) accepted an application seeking expanded approval of toripalimab, in combination with ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener The latest update ...

SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences. No financial terms of ...

The US Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) in combination with cisplatin and gemcitabine for the first-line treatment of adults with ...

A new immunotherapy, toripalimab, has the potential to change practice in the treatment of nasopharyngeal carcinoma (NPC), say experts. The drug is a monoclonal antibody that blocks programmed cell ...